Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 8/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23459130 | 1.00 | KMT2A (0.42) | KMT2AL3MBTL1CAPN1ATMNPC1 | |
| SCHEMBL17157145 | 0.86 | KMT2A (0.43) | KMT2ANPC1RAB9A | |
| SCHEMBL17157142 | 0.86 | KMT2A (0.43) | KMT2ANPC1RAB9A | |
| SCHEMBL1519869 | 0.86 | BACE1 (0.53) | L3MBTL1MME | |
| SCHEMBL20734850 | 0.85 | CTSS (0.54) | KMT2AATM | |
| SCHEMBL22154195 | 0.85 | CTSS (0.54) | KMT2AATM | |
| SCHEMBL19888360 | 0.83 | MME (0.43) | MME | |
| SCHEMBL9963890 | 0.80 | CTSS (0.56) | — | |
| SCHEMBL1520140 | 0.79 | BACE1 (0.38) | — | |
| SCHEMBL22120884 | 0.79 | MYC (0.41) | KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20210188827-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2021113506-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | ATM, CHEK2, CHEK1 | KMT2A 1328/4885L3MBTL1 2199/4885CAPN1 1782/4885 |
| US-20210188827-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | ATM, CHEK2, CHEK1 | KMT2A 1328/4885L3MBTL1 2199/4885CAPN1 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.